John Sawvel, DO
Neuromusculoskeletal Medicine & OMM · Beavercreek, OHNPI 1780682146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 31.6% of the total. Reporting peaked in 2019 at $879 and has fallen 97.6% since, to $21 in 2024.
Across 135 payments — averaging $10.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$442
- Pfizer$231
- Merck$178
- AstraZeneca$142
- Boehringer Ingelheim$60
- Lilly USA, LLC$58
- plus $289 from 10 others
What the payments were for
- Food & beverage$1,400100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $442 |
| Pfizer | 36 | $231 |
| Merck | 20 | $178 |
| AstraZeneca | 6 | $142 |
| Boehringer Ingelheim | 4 | $60 |
| Lilly USA, LLC | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| GSK | 3 | $39 |
| Abbott | 2 | $36 |
| AbbVie(2 entities) | 2 | $35 |
| Amgen | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $27 |
| Astellas Pharma US Inc | 1 | $14 |
| Corcept Therapeutics | 1 | $12 |
| Nalpropion Pharmaceuticals LLC | 1 | $11 |
How this compares
Too few neuromusculoskeletal medicine & omm providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 57 | $85,850 |
| EliquisApixaban | 30 | $40,991 |
| JanuviaSitagliptin Phosphate | 19 | $31,007 |
| MounjaroTirzepatide | 20 | $28,648 |
| TrulicityDulaglutide | 13 | $25,191 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,355 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,908 |
| Tizanidine Hcl | 31 | $3,404 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,207 |
| Levothyroxine Sodium | 276 | $2,839 |
| Celecoxib | 63 | $2,756 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $2,698 |
| Atorvastatin Calcium | 301 | $2,595 |
| Metoprolol Succinate | 156 | $2,385 |
| Bupropion XlBupropion Hcl | 46 | $2,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $60 | $85,85057 claims |
| Lilly USA, LLCMounjaro, Trulicity | $58 | $53,83933 claims |
| PfizerEliquis | $231 | $40,99130 claims |
| MerckJanuvia | $178 | $31,00719 claims |
| AstraZenecaSymbicort | $142 | $6,35511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromusculoskeletal medicine & omm providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other neuromusculoskeletal medicine & omm in Beavercreek
- Ann HabenichtBeavercreek$560
- Judith OconnellBeavercreek$539
- Carolyn GoldschmidtCleveland$80K
- Andreas SyllabaLoveland$4K
- Zachary WestTiffin$1K
- Zhan Tao YangWarrensville Heights$858
- Xavier DisabatoLima$614
- Kevin ReidDayton$164
- Korrie Beverley-WatersWarrensville Heights$125
- Anna WrightAthens$73
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.